Categories: News

Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

RESEARCH TRIANGLE PARK, N.C., May 01, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023.

The Science 37 management team will host a conference call to discuss these results on May 15, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13737724 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Science 37 website. A replay of the webcast will be available for approximately 90 days.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. As a single Metasite™ Science 37 reaches an expanded patient population beyond the traditional site and delivers the recruiting power of up to 20 sites in one with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own home, at their local community provider, or at a traditional site when needed. The Science 37 Metasite is powered by a proprietary technology platform, in addition to in-house investigators, mobile nurses, and remote coordinators that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

Contacts:

MEDIA INQUIRIES:
Grazia Mohren
Science 37
Email: pr@science37.com

INVESTOR RELATIONS:
Steve Halper
LifeSci Advisors
Email: shalper@lifesciadvisors.com

Staff

Recent Posts

Awakn Life Sciences Announces Shareholder Approval of Arrangement

Toronto, Ontario--(Newsfile Corp. - April 23, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC…

14 minutes ago

Tsingke Gene Leads a Delivery Revolution with “Calendar Day Delivery”

BEIJING, April 23, 2025 /PRNewswire/ -- In March 2025, Tsingke pioneered the industry's first full-range "Calendar Day…

2 hours ago

Kanazawa University Research: Visualizing the Mechanics of Hormone-Driven Gene Activation: Insights into Breast Cancer

KANAZAWA, Japan, April 23, 2025 /PRNewswire/ -- Scientists at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have…

2 hours ago

Clarivate Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and Execution

New solution provides integrated provider intelligence and real-world data to optimize targeting, strategic planning and…

2 hours ago

SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies

Revolutionary vibration device offers pain relief for finger pricks, GLP-1 shots, and wellness injections BOCA…

8 hours ago

Delota Provides Corporate Update and Early Redemption of Convertible Debentures

Vaughan, Ontario--(Newsfile Corp. - April 22, 2025) - Delota Corp. (CSE: NIC) (FSE: S62) ("Delota"…

12 hours ago